90 related articles for article (PubMed ID: 22891267)
1. Hepatitis B, rituximab, screening, and prophylaxis: effectiveness and cost effectiveness.
Hay AE; Meyer RM
J Clin Oncol; 2012 Sep; 30(26):3155-7. PubMed ID: 22891267
[No Abstract] [Full Text] [Related]
2. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis.
Zurawska U; Hicks LK; Woo G; Bell CM; Krahn M; Chan KK; Feld JJ
J Clin Oncol; 2012 Sep; 30(26):3167-73. PubMed ID: 22711851
[TBL] [Abstract][Full Text] [Related]
3. [Risk of reactivation of hepatitis B in patients with the lymphoma HBsAg negative , anti-HBc positive treated with rituximab-CHOP].
Pariente A
Rev Prat; 2014 Mar; 64(3):324. PubMed ID: 24851363
[No Abstract] [Full Text] [Related]
4. HBV reactivation in immunosuppressed patients: prevention or containment?
Ludwig E
Hepatology; 2014 Jun; 59(6):2062-4. PubMed ID: 24753022
[No Abstract] [Full Text] [Related]
5. Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma.
Li X; Lin Q; Dong M; Wen JY; Wei L; Ma XK; Chen ZH; Wu XY
Leuk Lymphoma; 2010 Sep; 51(9):1678-85. PubMed ID: 20807095
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism at
Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
[No Abstract] [Full Text] [Related]
7. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.
Hsu C; Tsou HH; Lin SJ; Wang MC; Yao M; Hwang WL; Kao WY; Chiu CF; Lin SF; Lin J; Chang CS; Tien HF; Liu TW; Chen PJ; Cheng AL;
Hepatology; 2014 Jun; 59(6):2092-100. PubMed ID: 24002804
[TBL] [Abstract][Full Text] [Related]
8. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
10. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
[TBL] [Abstract][Full Text] [Related]
11. Hope for very elderly patients with diffuse large B-cell lymphoma.
Ribera JM
Lancet Oncol; 2011 May; 12(5):412-3. PubMed ID: 21482185
[No Abstract] [Full Text] [Related]
12. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
13. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous drug Reactions: Chemotherapy-induced hyperpigmentation.
Hernández-Aragüés I; Baniandrés-Rodríguez O; Vilas-Boas PT; Conde-Montero E; Suárez-Fernández R
Eur J Dermatol; 2017 Dec; 27(6):679-680. PubMed ID: 29311047
[No Abstract] [Full Text] [Related]
15. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
16. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms.
Crespo J; Esteban R; Torres C; Oyagüez I; Casado MÁ; Buti M
Rev Esp Enferm Dig; 2017 Sep; 109(9):619-626. PubMed ID: 28648087
[TBL] [Abstract][Full Text] [Related]
18. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
19. Large gastrosplenic fistula after effective treatment of abdominal diffuse large-B-cell lymphoma.
Palmowski M; Zechmann C; Satzl S; Bartling S; Hallscheidt P
Ann Hematol; 2008 Apr; 87(4):337-8. PubMed ID: 17929016
[No Abstract] [Full Text] [Related]
20. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
